Extended endocrine therapy use and decision making after breast cancer diagnosis.

ABSTRACT:

Background

Adjuvant endocrine therapy is recommended to extend beyond 5 years for stage II breast cancer, with less consensus for extension in stage I. We aimed to understand use of and decision making about extended endocrine therapy.

Methods

Women aged 20-79 years diagnosed with stage I-II breast cancer in 2014-2015 and reported to Georgia and Los Angeles County Surveillance, Epidemiology, and End Results registries were surveyed at 7 months and again at 6 years postdiagnosis (n = 2361; response rate = 60%). Women with estrogen receptor-positive and/or progesterone receptor-positive disease were asked about their decision whether to continue therapy.

Results

Of 831 women, 591 had completed or were completing 5 years of endocrine therapy. Among those who had decided

SUBMITTER: Kurian AW 

PROVIDER: S-EPMC12342784 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature